Tenax Therapeutics to Present Phase 3 LEVEL Topline Data at ESC Congress, Expects August Results

Tenax Therapeutics will present Phase 3 LEVEL trial results at ESC Congress and now expects to report topline data in August 2026.Key Highlights:Original SEC Filing: TENAX THERAPEUTICS, INC. [ TENX ] - 8-K - Jul. 02, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying…

Tenax Therapeutics will present Phase 3 LEVEL trial results at ESC Congress and now expects to report topline data in August 2026.

Key Highlights:

LEVEL Phase 3 results to be presented in a Late-Breaking Clinical Science session at ESC Congress 2026.
Company expects to report topline LEVEL data in August 2026 and will proceed to database lock and analysis.
LEVEL evaluates oral levosimendan (TNX-103) in PH-HFpEF; enrollment of over 230 patients completed in March 2026.
Blinded sample size re-estimation in Dec 2025 showed >90% power to detect a 25m change in 6MWD, the primary endpoint.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.